Capital Research Global Investors Lowers Stock Position in IDEXX Laboratories, Inc. $IDXX

Capital Research Global Investors lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 607,754 shares of the company’s stock after selling 82,847 shares during the quarter. Capital Research Global Investors owned about 0.76% of IDEXX Laboratories worth $411,164,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Los Angeles Capital Management LLC raised its stake in shares of IDEXX Laboratories by 41.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 191,665 shares of the company’s stock worth $120,469,000 after acquiring an additional 56,230 shares in the last quarter. Cookson Peirce & Co. Inc. bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $700,000. Havemeyer Place LP bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $2,375,000. 111 Capital raised its stake in shares of IDEXX Laboratories by 72.2% during the 4th quarter. 111 Capital now owns 966 shares of the company’s stock worth $654,000 after acquiring an additional 405 shares in the last quarter. Finally, Pinebridge Investments LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $12,496,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on IDXX. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $562.16 on Monday. The firm has a market capitalization of $44.34 billion, a P/E ratio of 41.40, a PEG ratio of 3.08 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The company’s fifty day moving average price is $563.05 and its 200-day moving average price is $631.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.